Dr Reddy's launches antibiotic drug in US market

Tags: Companies
Dr Reddy's Laboratories Ltd has launched Moxifloxacin Hydrochloride tablets in the US market for the treatment of a wide range of diseases, including pneumonia, bronchitis and skin infections.

The drug was launched yesterday following the approval by the United States Food & Drug Administration (USFDA), DRL said in a press release today.

The tablets, a generic version of Avelox 400 mg, are available in bottle counts of 30, it said.

Bayer's Avelox is indicated for the treatment of community acquired pneumonia (CAP), acute exacerbations of chronic bronchitis (AECB), acute bacterial sinusitis (ABS), uncomplicated and complicated skin and skin structure infections (uSSSI and cSSSI), mild to moderate pelvic inflammatory disease (PID), and complicated intra-abdominal infections (cIAI), according to Avelox official website.

According to IMS Health, Avelox (moxifloxacin HCl) tablets had a sales figure of approximately $195 millions in 2013, the release said.

Shares of DRL were trading at Rs 2,800 apiece on the BSE during afternoon trade.

EDITORIAL OF THE DAY

  • Realtors must lower the ratio of capital value to rental income to entice buyers

    Real estate prices are likely to witness a correction in the coming festival season, according to a report put out in this newspaper on Monday, with p

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

Sarthak Raychaudhuri

vice-president, HR, Asia South Whirlpool of India

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

TODAY'S COLUMNS

BK Chaturvedi

Undermining demographic dividend

Development and economic growth of nations is built upon the ...

Kuruvilla Pandikattu

Imperfection makes you more human

For all those who live in fear of making a ...

Shona Adhikari

Artistic focus on women's empowerment

The focus on the girl child remains an important one ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture